Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Bayer's steady cash flows from healthcare and crop science products should enable the company to both reduce debt and service current debt levels. However, the high debt levels and slow near-term ...

The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

Biogen BIIB will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate for ...

In a major relief to Zydus Lifesciences, the Delhi High Court dismissed F. Hoffmann-La Roche's plea seeking disclosure of ...

DAEJEON, South Korea I July 28, 2025 I Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal ...

Explore the evolving biosimilars landscape with expert insights on development, regulation, and global health harmonization ...

Amgen Inc. (NASDAQ:AMGN) is on the hunt for its next breakthrough drug— a common pursuit among pharmaceutical companies ...

GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals ...

On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement ...

Swiss pharma giant Roche Holding AG (RHHBY) reported sales of CHF 30.9 billion for the first half of 2025, up 4% year over ...